PT2173376E - Vacinas de influenza multiepitópicas multiméricas - Google Patents

Vacinas de influenza multiepitópicas multiméricas Download PDF

Info

Publication number
PT2173376E
PT2173376E PT87897385T PT08789738T PT2173376E PT 2173376 E PT2173376 E PT 2173376E PT 87897385 T PT87897385 T PT 87897385T PT 08789738 T PT08789738 T PT 08789738T PT 2173376 E PT2173376 E PT 2173376E
Authority
PT
Portugal
Prior art keywords
influenza vaccines
multimeric multiepitope
multiepitope influenza
multimeric
vaccines
Prior art date
Application number
PT87897385T
Other languages
English (en)
Portuguese (pt)
Inventor
Tamar Ben-Yedidia
Yossi Singer
Original Assignee
Biondvax Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondvax Pharmaceuticals Ltd filed Critical Biondvax Pharmaceuticals Ltd
Publication of PT2173376E publication Critical patent/PT2173376E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PT87897385T 2007-08-02 2008-08-03 Vacinas de influenza multiepitópicas multiméricas PT2173376E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02

Publications (1)

Publication Number Publication Date
PT2173376E true PT2173376E (pt) 2015-07-30

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87897385T PT2173376E (pt) 2007-08-02 2008-08-03 Vacinas de influenza multiepitópicas multiméricas

Country Status (17)

Country Link
US (2) US8747861B2 (enExample)
EP (1) EP2173376B1 (enExample)
JP (1) JP5654345B2 (enExample)
KR (1) KR101580660B1 (enExample)
CN (1) CN101795709B (enExample)
AU (1) AU2008281384C1 (enExample)
BR (1) BRPI0815008B8 (enExample)
CA (1) CA2695399C (enExample)
DK (1) DK2173376T3 (enExample)
EA (1) EA017887B1 (enExample)
ES (1) ES2539818T3 (enExample)
HR (1) HRP20150479T1 (enExample)
HU (1) HUE025149T2 (enExample)
MX (1) MX2010001284A (enExample)
PL (1) PL2173376T3 (enExample)
PT (1) PT2173376E (enExample)
WO (1) WO2009016639A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
CA2976814C (en) 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US9408873B2 (en) 2010-08-23 2016-08-09 Kang Stem Biotech Co., Ltd. Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
EP2678361A4 (en) * 2011-02-21 2015-06-03 Vaxinnate Corp COMPOSITIONS WITH IMPROVED IMMUNOGENICITY AND / OR REDUCED REACTIVITY AND METHOD OF USE THEREOF
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
WO2013037804A1 (en) * 2011-09-12 2013-03-21 Laboratorios Del Dr. Esteve, S.A. Method for monitoring cytotoxic t lymphocyte (ctl) responses by a delayed-type hypersensitivity reaction using defined ctl viral epitopes
CN104203272A (zh) * 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
CN104395346A (zh) * 2012-04-02 2015-03-04 弗利亚生物技术公司 重组木瓜花叶病毒外壳蛋白及其在流感疫苗中的应用
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
US20140193484A1 (en) * 2013-01-10 2014-07-10 Sylvie Carine Bertholet Girardin Influenza virus immunogenic compositions and uses thereof
CA2944768C (en) 2014-04-03 2022-08-30 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
SG10202108573TA (en) * 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
EP3562498A4 (en) 2016-12-28 2020-10-28 Invvax, Inc. INFLUENZA VACCINES
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
CN111556896A (zh) * 2017-12-21 2020-08-18 株式会社绿色生物医药 交叉免疫抗原疫苗及其制备方法
EP3774841A1 (en) 2018-08-27 2021-02-17 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
EP3851120A4 (en) * 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
JP2023513720A (ja) * 2020-02-14 2023-04-03 ユニバーシティ オブ ワシントン 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
PT761231E (pt) * 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
EP0625043B1 (en) * 1992-09-16 2002-03-20 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
SK117395A3 (en) * 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) * 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
AU732856B2 (en) * 1997-05-20 2001-05-03 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
CA2297786C (en) 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
JP4426091B2 (ja) * 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
AU6253898A (en) * 1997-12-16 1999-07-05 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
US6630161B1 (en) 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001024810A1 (en) 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
DK1294892T3 (da) 2000-06-23 2008-01-28 Wyeth Corp Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
AU2003279750A1 (en) * 2002-06-28 2004-01-19 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
WO2004080403A2 (en) 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine
US7108679B2 (en) * 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
CA2589553C (en) * 2004-12-16 2014-02-18 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
WO2006069262A2 (en) 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
US20090104216A1 (en) * 2005-06-01 2009-04-23 Variation Biotechnologies, Inc. Peptide-Based Influenza Vaccine Formulation
US7260958B2 (en) * 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
EP1945253A2 (en) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
ES2385842T3 (es) * 2005-12-06 2012-08-01 Yeda Research And Development Co., Ltd. Vacuna mejorada contra la gripe
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2008039267A2 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
KR20100075843A (ko) 2007-08-21 2010-07-05 다이나박스 테크놀로지 코퍼레이션 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법

Also Published As

Publication number Publication date
WO2009016639A3 (en) 2009-04-30
CA2695399C (en) 2017-10-17
JP5654345B2 (ja) 2015-01-14
BRPI0815008B8 (pt) 2021-05-25
WO2009016639A2 (en) 2009-02-05
CN101795709A (zh) 2010-08-04
US20140286982A1 (en) 2014-09-25
HUE025149T2 (hu) 2016-01-28
AU2008281384A1 (en) 2009-02-05
US20110182974A1 (en) 2011-07-28
KR101580660B1 (ko) 2015-12-28
KR20100045473A (ko) 2010-05-03
PL2173376T3 (pl) 2015-08-31
AU2008281384C1 (en) 2012-08-16
US9353159B2 (en) 2016-05-31
HK1142809A1 (en) 2010-12-17
JP2010535026A (ja) 2010-11-18
EP2173376B1 (en) 2015-03-25
CA2695399A1 (en) 2009-02-05
AU2008281384B2 (en) 2012-02-16
HRP20150479T1 (hr) 2015-07-17
US8747861B2 (en) 2014-06-10
ES2539818T3 (es) 2015-07-06
EA201070219A1 (ru) 2010-08-30
DK2173376T3 (en) 2015-06-29
MX2010001284A (es) 2010-08-31
CN101795709B (zh) 2013-07-17
EA017887B1 (ru) 2013-03-29
EP2173376A2 (en) 2010-04-14
BRPI0815008B1 (pt) 2019-11-19

Similar Documents

Publication Publication Date Title
PL2173376T3 (pl) Multimeryczne wieloepitopowe szczepionki przeciwko grypie
SI2185191T1 (sl) Cepiva proti influenci z majhnimi dodatki
IL196024A0 (en) Influenza vaccine
ZA200904923B (en) Vaccine
IL201782A0 (en) Vaccine
GB0717911D0 (en) Vaccine
GB0711858D0 (en) Vaccine
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA201004303B (en) Vaccine
AP2010005166A0 (en) Vaccines
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
PT2422810E (pt) Vacina da gripe
ZA201100962B (en) Influenza vaccines
GB0700135D0 (en) Vaccine
GB0710538D0 (en) Vaccine
ZA201003851B (en) Vaccine
ZA200900062B (en) Influenza vaccine
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0618195D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
GB0623865D0 (en) Influenza vaccine
GB0700760D0 (en) Vaccine
GB0712062D0 (en) Vaccine